bluuebunny/crossref_metadata_2025_split huggingface dataset:
Stem anteversion is not affected by proximal femur geometry in robotic-assisted total hip arthroplasty
Authors: Marcovigi Andrea , Grandi Gianluca , Bianchi Luca , Zambianchi Francesco , Pavesi Marco , Catani Fabio 
Published: June 2024

Abstract
Background
In the present study, the surgeon aimed to align the stem at 5° to 25° in anteversion. The robotic technology was used to measure stem anteversion with respect to proximal femur anteversion at different levels down the femur.

Methods
A total of 102 consecutive patients underwent robotic-arm-assisted total hip arthroplasty (RTHA). 3D CT-based preoperative planning was performed to determine femoral neck version (FNV), posterior cortex anteversion (PCA), anterior cortex anteversion (ACA), and femoral metaphyseal axis anteversion (MAA) at 3 different levels: D (10 mm above lesser trochanter), E (the midpoint of the planned neck resection line) and F (head-neck junction). The robotic system was used to define and measure stem anteversion during surgery.

Results
Mean FNV was 6.6° (SD: 8.8°) and the mean MAA was consistently significantly higher than FNV, growing progressively from proximal to distal. Mean SV was 16.4° (SD: 4.7°). There was no statistically significant difference (P = 0.16) between SV and MAA at the most distal measured level. In 96.1% cases, the stem was positioned inside the 5°–25° anteversion range.

Conclusions
Femoral anteversion progressively increased from neck to proximal metaphysis. Aligning the stem close to femoral anteversion 10 mm above the lesser trochanter often led to the desired component anteversion.
Multivariate statistical regression analysis and relative quantification based on dimensional-reduction method to compare the taste-active components of different chicken breeds
Authors: Xu Na , Wang Hao , Liu Lei , Xu Xinglian , Wang Peng 
Published: June 2024

AbstractTo compare the difference of non-volatile taste-active flavor components of different chicken breeds, four Chinese native yellow feather broilers including Langshan chicken, Chongren chicken, Luyuan chicken and Wenchang chicken were used in the experiment. The contents of free amino acids, 5'-nucleotides and minerals were determined by standard method, and then five principal components were extracted from the multi-index system based on the principal component analysis (PCA). Combined with the Mahalanobis distance analysis method and sensory evaluation results, the advantages and characteristics of each chicken breed were evaluated. The results showed that different kinds of chicken had their own advantages in different evaluation dimensions. The Equivalent umami concentration (ECU) of Wenchang chicken, which had the highest content of amino acids, was 12 g monosodium glutamate (MSG)/100 g, indicating the umami taste of it was very intense. The indexes of Langshan chicken were relatively uniform, with slightly higher mineral content, its overall Mahalanobis distance score was more similar to the "best standard". According to the Mahalanobis distance score, although the difference in amino acid content among each species was the largest, the overall score was more affected by the content of minerals and nucleotides, and there was interaction between each nutrient, which had an impact on the overall Mahalanobis distance score. The sensory evaluation results indicated that Wenchang chicken was the most superior among the taste of the four varieties investigated. Finally, taste compounds affecting the difference of chicken varieties were analyzed by partial least squares regression (PLS), resulting in order of mineral (Ca2+, Mg2+, PO43−) > nucleotide (AMP, IMP) > amino acid. This could provide a theoretical basis for quantitative oriented flavor processing and consumer choice of chicken.
Graphical Abstract
Depressive symptoms and coping patterns in a sample of Egyptian mothers of ADHD children
Authors: Serag Rehab , Hamed Marwa Abdel Meguid , Mahmoud Dalia Abdel Moneim , Elabd Esraa Fakhry Mahmoud , Kasem Rania Elsayed 
Published: June 2024

Abstract
Background
Attention-deficit/hyperactivity disorder (ADHD) is considered to be one of the most common neurodevelopmental conditions found in children. The global prevalence in the age group 6–17 years falls between 2 and 18%. Studies have found that mothers of ADHD children are more prone to experience depression, anxiety, social isolation, stress, and self-blame.

Aims and objectives
To assess the prevalence of depression and its severity among mothers with children found to have ADHD compared to mothers of the control group, we also investigate the coping mechanisms employed by mothers with ADHD children and identify any potential correlation between coping strategies utilized by mothers in the case group and the severity of depression.

Patients and methods
In this cross-sectional study, we recruited 100 participants from the outpatient child psychiatry clinic at Ma’amoura Psychiatric Hospital in Alexandria, Egypt. Two participant groups were assembled: Group I (case) consisted of 50 mothers whose children had ADHD, and Group II (control) consisted of 50 mothers whose children did not have ADHD. Both groups underwent the General Health Questionnaire (GHQ-28), Beck Depression Inventory (BDI-II), and Coping Orientation to Problems Experienced (COPE) inventory.

Results
A significant relationship was observed between the Beck Score and hyperactive and combined ADHD types; however, no significant correlation was found between the Beck Score and the inattentive ADHD type. Regarding the coping styles with stress, the current study’s results found that in (case group) turning to religion had the highest sub-scale mean, followed by seeking social support and emotional support, while the lowest sub-scale score mean was humor, followed by denial. By employing univariate logistic regression analysis to identify depression predictors in group I, the results showed that the increase in the score of less useful coping by 1 was a probable factor to increase the possibility of depression by OR = 1.438 (1.186–1.743). Combined and hyperactive ADHD types were found to increase the risk of depression by OR 6.706 (1.309–34.353).

Conclusion
Depressive complaints were more prevalent among mothers of children with ADHD compared to the control group. We found a statistically important relationship between Beck Depression Scores (depressive symptom severity) in mothers with ADHD children and having hyperactive or combined ADHD types in their children. We also found a statistically significant positive correlation between the severity of depression and some coping styles as turning to religion and seeking social support.
A case of intermittent bilious emesis in a term neonate: a case report and brief review of literature
Authors: Mudugere Asha , Pradhan Antaryami , Kumar Vijay , Nanda Debasish 
Published: June 2024

Abstract
Background
Neonatal intestinal obstruction is a complex condition that poses challenge in management. Prompt recognition and appropriate management are crucial to prevent complications. We present a case of a term neonate with intermittent bilious vomiting.

Case presentation
The baby underwent routinely performed investigations, including abdominal radiography and ultrasound, which provided inconclusive results. However, contrast-enhanced computed tomography revealed a web at duodenojejunal flexure. Exploratory laparotomy confirmed the diagnosis, and surgical intervention was performed. The baby’s postoperative course was prolonged with a gradual transition from parenteral nutrition to enteral feeds.

Conclusion
This case highlights a rare cause of intestinal obstruction, the unusual location of duodenal web, the importance of maintaining a high index of suspicion for intestinal obstruction, even in the absence of classical signs, and the value of utilizing contrast-enhanced computed tomography when initial investigations are inconclusive.
A phase 1 study of liposomal irinotecan in patients with advanced breast cancer.
Authors: Fan Ying , Zhang Qingyuan , Yan Min , Qu Xiujuan , Yin Yongmei , Sun Tao , Yang Jin , Wang Ying , Wang Xu , Niu Zhaofeng , Wang Xinshuai , Sun Sanyuan , Zhao Weihong , Liu Yanping , Miao Niu , Xuemin Zhao , Xu Binghe 
Published: June 2024

1080 Background: Liposomal irinotecan (HE072) is a liposomal formulation that encapsulates irinotecan in a lipid bilayer vesicle, and as a generic drug, had been approved in China, recently, in patients with pancreatic cancer after gemcitabine treatment. Advanced triple negative breast cancer (TNBC) has very poor prognosis and limited treatment choices. Here we present results of breast cancer treated with HE072 in patients with highly pre-treated metastatic TNBC and HER2 negative breast cancer brain metastasis (BCBM). Methods: HE072-CSP-002 was a phase 1 study, consisting of two parts, dose escalation and expansion part (part 1) and expansion cohort part (part 2). In part 1, standard 3+3 design was used to investigate up to three dose levels of HE072 (50 mg/m2, 70 mg/m2 and 90 mg/m2), up to 6-9 additional subjects may be enrolled for dose expansion. In part 2, patients were enrolled in two cohorts (TNBC cohort and BCBM cohort), and received HE072 70 mg/m2 every two weeks (Q2W). The primary endpoints were the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), and the incidence and severity of treatment emergent adverse events (TEAEs). Secondary endpoints included progression free survival (PFS), objective response rate (ORR), overall survival (OS). Results: As of June 5th, 2023, 119 patients were enrolled, including 101 patients with TNBC and 18 patients with HER2 negative BCBM (part 1: n=27; part 2: n=92). In the part 1, one dose-limiting toxicity (grade 3 nausea and grade 3 vomiting) was observed at 70 mg/m2 dose level, and MTD was not reached. A total of 115 patients (96.6%) had at least one TEAEs of any grade, and 55 patients (46.2%) had ≥grade 3 TEAEs. The most common ≥grade 3 TEAEs related to HE072 included neutropenia (21.0%), leukopenia (18.5%), diarrhea (10.1%), anemia (9.2%) and hypokalemia (8.4%). Eighty-three (82.2%) of the 101 patients with TNBC were evaluable for response. After a median follow-up of 10.1 months (range 8.8-10.8), 22 patients (26.5%, 95%CI 17.4-37.3) achieved overall response, which were all partial response and 58 patients (69.9%, 95%CI 58.8-79.5) achieved disease control. The median PFS and OS were 4.8 months (95%CI 3.9-5.8) and 14.1 months (95%CI 11.2-not reached), respectively. 12(66.7%) of the 18 patients with HER2 negative BCBM were evaluable for response. 1 patient (8.3%, 95%CI 0.2, 38.5) achieved overall response, which is partial response and 8 patients (66.7%, 95%CI 34.9, 90.1) achieved disease control. The median PFS was 5.6 months (95%CI 1.4~ not reached), 12-month OS rate was 55.5%. Conclusions: HE072 exhibited excellent antitumor activity in heavily pre-treated patients with TNBC and HER2 negative BCBM with acceptable safety profiles. 70 mg/m2 Q2W was determined as the RP2D. Further clinical trials are under plan. Clinical trial information: NCT04728035 .
Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results.
Authors: Seneviratne Lasika C. , Harnden Kathleen Kiernan , Blau Sibel , Danso Michael A. , Berz David , Guaqueta Delia Constanza , Schwerkoske John F. , O'Shaughnessy Joyce , Patt Debra A. , Bardia Aditya , McCann Kelly Elizabeth , Beelen Andrew Paul , Zhang Jingshan , Yi John S. , Hurvitz Sara A. , Mardones Mabel Alejandra 
Published: June 2024

1091 Background: Trilaciclib, a reversible cyclin-dependent kinase 4/6 inhibitor, protects hematopoietic stem and progenitor cells during chemotherapy (myeloprotection). In a phase 2 trial in mTNBC (NCT02978716), administering trilaciclib prior to chemotherapy enhanced T-cell activity and modulated antitumor immunity. In a phase 3 trial (ASCENT; NCT02574455), the antibody–drug conjugate SG significantly extended overall survival (OS) versus single-agent chemotherapy (12.1 vs 6.7 months) but was associated with increased neutropenia (any grade, 63% vs 43%; grade 3/4, 51% vs 33%) and diarrhea (any grade, 59% vs 12%; grade 3/4, 10% vs < 1%). This phase 2 single-arm trial was designed to assess safety and efficacy of trilaciclib prior to SG in mTNBC (NCT05113966). Methods: Eligible patients (≥ 2 prior systemic therapies [≥ 1 in the metastatic setting]; measurable disease; confirmed hormone receptor- and human epidermal growth factor receptor 2-negative status; Eastern Cooperative Oncology Group performance status 0 or 1) received intravenous trilaciclib 240 mg/m2 prior to SG 10 mg/kg on days 1 and 8 of each 21-day cycle until disease progression or toxicity. Tumor assessments occurred at screening, every 6 weeks through week 26, then every 9 weeks until disease progression or subsequent anticancer therapy. Endpoints included antitumor efficacy, myeloprotection, and safety and tolerability. Results: As of January 2, 2024, 30 female patients had been enrolled (median age, 56 years) and completed a median 6 (range, 2–29) cycles. Median follow-up was 11.2 months. Safety is summarized in the Table. The confirmed overall response rate (95% CI) was 23.3% (9.9–42.3), the clinical benefit rate was 46.7% (28.3–65.7), and the median duration of response was 9.1 (4.0–not estimable) months. Median progression-free survival was 4.1 (2.2–7.3) months. OS data are not yet mature; currently, median OS among patients receiving trilaciclib prior to SG is 17.9 (9.9–not estimable) months. Conclusions: Adding trilaciclib prior to SG reduces the rate and severity of multiple adverse events, notably neutropenia and diarrhea, compared with results from trials of SG alone. Preliminary data suggest clinically meaningful OS outcomes among patients receiving trilaciclib prior to SG compared with historical data for SG alone; however, caution should be exercised when interpreting results from cross-trial comparisons. Mature OS data will be presented. Clinical trial information: NCT05113966 . [Table: see text]
Interventions of the nurse navigator in the identification and management of toxicities after the start of treatment in patients with cancer using antineoplastic therapy.
Authors: Messias Anna Carolina R , Bergerot Cristiane Decat , Faria Andre , Gregoli Camila Tolomelli , Vidal Alice Sousa , Carneiro Juliana Torres , Ferrari Bruno Lemos 
Published: June 2024

12139 Background: Monitoring symptoms during chemotherapy is crucial as patients experience adverse effects, requiring therapeutic modifications, supportive care, and education. Patient navigation provides individualized assistance, overcoming barriers to healthcare access for patients, families, and caregivers. A previous study (Tabriz et al. JAMA Netw Open 2023) has shown that 52% of emergency room (ER) visits can be preventable. Thus, this study sought to determine effect of a nurse navigation program on reducing the rate of ER visit. Methods: This retrospective study was conducted from June to December 2023 in two cancer centers within the Oncoclinicas Network, located in the Southeast and Northwest regions of Brazil. Eligible patients were diagnosed with breast, lung, and gastrointestinal cancer, and were undergoing treatment with chemotherapy and/or immunotherapy. These patients were monitored by nurse navigators at post-therapy. Interventions were categorized as home management (care provided at patient’s home), outpatient (referral to the treatment clinic), and hospital (referral to emergency care). All toxicities were graded according to the Common Terminology Criteria for Adverse Events 5.0. Results: A total of 531 patients were included in the analysis, with the majority aged over 61 years old (44.4%), diagnosed breast (%) or colon (%) cancers. Throughout the six month study period, 3,201 toxicities were identified, with the majority graded between 1 and 2 (95.9%). This resulted in 91.9% of patients being managed at home or referred to the outpatient care. The cumulative proportion of patients having their symptoms managed at home or outpatient care is significantly higher than historical controls (P=0.001). Conclusions: Our findings highlight the effectiveness of a nurse navigation program in managing toxicities and symptoms, preventing ER visit. These findings underscore the importance of this program in optimizing patient care and reducing the burden on healthcare facilities. Further research and implementation of such programs may contribute to improved outcomes and patient satisfaction in oncological care.
Cancer clinical trial participation in socioeconomically vulnerable patients: A risk model to aid in targeted interventions.
Authors: Szarama Katherine , Unger Joseph M. 
Published: June 2024

1529 Background: In patients with cancer, those with lower income are 30% less likely to participate in clinical trials. Lower income individuals face direct and indirect costs that can make participation in a clinical trial prohibitive. However, a broader evaluation of specific behavioral, information, insurance, and area-level variables that could contribute to this disparity has not been conducted. We aimed to develop and validate a model to identify socioeconomically vulnerable patients at high risk of non-participation in clinical trials. Methods: We used data from the Health Information National Trends Survey (HINTS), a national cross-sectional survey about knowledge of, attitudes toward, and use of health-related information. We analyzed HINTS survey databases that included questions about whether patients with cancer participated in a clinical trial (survey years 2014, 2017, and 2020). We examined 21 different demographic, socioeconomic, behavioral, geographic, and health information questions. We derived a risk model to predict clinical trial participation in a random set of 60% of participants using best subset selection with k-fold cross validation. The derived model was validated in the remaining 40% of participants. Logistic regression was used. Results: We examined N=1,023 participants with household income <$75,000, the current median in the U.S. In the training dataset of n=614 participants, a model with 5 variables was identified. Non-Hispanic White patients and patients without a college education, with high levels of distrust, with high levels of anxiety or depression, and from non-urban areas were all at lower risk of trial participation. We summed the adverse risk factors for all individuals; a risk score with 4 levels was constructed based on distribution quartiles. In the independent validation cohort (n=409), each increase in level of adverse risk factors was associated with a 42% reduction in the odds of trial participation (OR=0.58, 95%-CI, 0.40-0.84, p=.004), indicating successful model validation. Among all individuals, trial participation rates decreased from 18.6% to 7.5% to 4.6% to 2.8%, respectively, as the number of adverse risk factors increased (in quartiles) from 0-1 to 2 to 3 to 4-5. Individuals with 4 or 5 risk factors (vs. those with 0-1 factors) were 87% less likely to participate (OR=0.13, 95% CI, 0.05-0.31, p<.0001). Conclusions: We developed and validated a 5-variable risk model that identified a large set of lower income individuals at lower risk of trial participation. In a first-time observation, psychosocial variables were shown to be meaningful predictors of lower trial participation. These findings could aide in the early identification of patients who may benefit from additional support to navigate the treatment trial decision making process, in the name of more equitable participation in trials for all patients.
Continuous remote monitoring of performance status in patients with NSCLC through fitness tracker–derived life-log data.
Authors: Bang Yeong Hak , Lee Suyeon , Kim Taehee , Suh Hongyiel , Kim Mansu , Park Sehhoon 
Published: June 2024

1568 Background: Traditional methods for assessing the performance status of cancer patients often rely on clinical evaluations and patient-reported histories. This study utilizes life-log data derived from fitness trackers (FTs) in patients with non-small cell lung cancer (NSCLC) to offer a comprehensive and dynamic perspective on performance status throughout their treatment. Methods: Patients with NSCLC scheduled for a minimum of 12 weeks of treatment were enrolled. Custom software facilitated the remote collection of life-log data from participants' FTs (Fitbit Inspire 3), encompassing step count, calories burned, heart rate, sleep patterns, etc. Quality of life surveys assessing patient-reported outcomes (PROs) were completed during regular visits (every 3 weeks) and unscheduled visits (USV), in addition to collecting clinical data such as laboratory parameters and body composition metrics. An end-of-monitoring survey assessed participants' familiarity with this monitoring approach. The study aimed to correlate FT data with clinical parameters and identify patterns predictive of treatment related USVs. Results: Of the 98 enrolled patients, 69 patients (70.4%) completed the 12-week follow-up. The cohort predominantly consisted of older adults (≥65 years) (55.1%) and patients in palliative care (75.5%), with most undergoing cytotoxic chemotherapy (66.3%) and some receiving oral agents (20%). FT-based remote monitoring revealed that older patients had a comparable 12-week completion rate to younger patients. (69.2% vs. 76.2%, P=0.604). Analysis of life-log data from three days before a visit (D-3) to the visit day (D0) showed significant reductions in average step counts ( P=0.022) and walking distance ( P=0.021) for USVs compared to regular visits, while resting heart rate (HR) showed a significant increase for USVs ( P=0.049). PRO-based PROMIS physical function scores and EQ-5D-3L scores showed a significant correlation with both D-3 to D0 acquired resting HR ( P<0.001, P=0.002) and average step counts ( P=0.011, P=0.013), respectively. End of monitoring survey was done from 72 participants indicating high satisfaction and familiarity with the FT-based remote monitoring system, median score of 90 out of 100. Conclusions: FT-derived life-log data effectively captured dynamic performance status in NSCLC patients, correlating with clinical outcomes and PRO. These findings support further research into FT data's predictive value for clinical interventions, underscoring its potential in personalized remote patient management.